Efficacy of linezolid containing regimens in multidrug-resistant tuberculosis (MDR-TB) adults: the current scientific evidence
| First author [ref.] | Sample size | Design | MDR-/ XDR-TB | Culture conversion | Treatment success | Daily linezolid dosage mg |
| Observational studies | ||||||
| Sotgiu [31] | 121 | Systematic review of the observational studies | 82/39 | 100/107 (93.5) | 99/121 (81.8) | 300, 400, 450, 600 (once and twice daily) |
| Zhang [35] | 15 | Retrospective | 0/15 | 9/15 (60.0) | 9/15 (60.0) | 600 once daily |
| Xu [36] | 18 | Retrospective | 3/15 | 16/18 (88.9) | 9/18 (50.0) | 600 twice daily, 900 |
| Experimental studies | ||||||
| Lee [32] | 39 | Randomised, phase 2a | 0/39 | 34/38 (89) | 600 once daily, 300 once daily | |
| Tang [34] | 65 | Randomised, controlled | 0/65 | 26/33 (78.8) | 23/33 (69.7) | 300, 600 (once and twice daily) |
Data are presented as n or n/N (%). XDR-TB: extensively drug-resistant tuberculosis.